Zomedica Corp. (ZOMDF): Nasdaq/NYSE listing notice — Zomedica gets NYSE American deficiency notice for low share price (<$0.20 avg)

Zomedica Corp.

30-trading day average share price fell below $0.20, triggering Section 1003(f)(v) non-compliance.
Cure deadline is March 12, 2024; Company may effect a reverse stock split.
No immediate delisting; shares continue trading on NYSE American during cure period.
Management remains well-capitalized; business operations and SEC reporting unaffected.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

Zomedica Corp. received a nyse_american deficiency notice notice regarding minimum bid price (rules 1003(f)(v), 1009).

Exchange: nyse american
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 1003(f)(v), 1009

Exact text from the filing

September 12, 2023, Zomedica Corp. (the “Company”) received a deficiency letter (the “Letter”) from the NYSE American LLC (the “NYSE American”) indicating that the Company was not in compliance with the NYSE American continued listing standards set forth in Section 1003(f)(v) of the NYSE American Company Guide (the “Company Guide”) because the Company’s common shares were selling for a substantial period of time at a low price per share, which the NYSE American determined to be a 30-trading day average of less than $0.20 per share. The Letter does not result in the immediate delisting of the C

View on SEC.gov

Browse all listing & compliance notices →

Zomedica Corp. filing history →

Source: SEC EDGAR

accession 0001654954-23-011829

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.